Please use this identifier to cite or link to this item:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma

AuthorsRojas, Elizabeta A.; Corchete, Luis A.; San-Segundo, Laura; Martínez-Blanch, Juan F.; Codoñer, Francisco M.; Paíno, Teresa CSIC ORCID; Puig, Noemi; García-Sanz, Ramón; Mateos, Maria Victoria; Ocio, Enrique M. CSIC ORCID ; Misiewicz-Krzeminska, Irena; Gutiérrez, Norma Carmen
Issue Date2017
PublisherAmerican Association for Cancer Research
CitationClinical Cancer Research 23(21): 6602-6615 (2017)
Abstract[Purpose]: The search for new drugs that control the continuous relapses of multiple myeloma is still required. Here, we report for the first time the potent antimyeloma activity of amiloride, an old potassium-sparing diuretic approved for the treatment of hypertension and edema due to heart failure. [Experimental Design]: Myeloma cell lines and primary samples were used to evaluate cytotoxicity of amiloride. In vivo studies were carried out in a xenograft mouse model. The mechanisms of action were investigated using RNA-Seq experiments, qRT-PCR, immunoblotting, and immunofluorescence assays. [Results]: Amiloride-induced apoptosis was observed in a broad panel of multiple myeloma cell lines and in a xenograft mouse model. Moreover, amiloride also had a synergistic effect when combined with dexamethasone, melphalan, lenalidomide, and pomalidomide. RNA-Seq experiments showed that amiloride not only significantly altered the level of transcript isoforms and alternative splicing events, but also deregulated the spliceosomal machinery. In addition, disruption of the splicing machinery in immunofluorescence studies was associated with the inhibition of myeloma cell viability after amiloride exposure. Although amiloride was able to induce apoptosis in myeloma cells lacking p53 expression, activation of p53 signaling was observed in wild-type and mutated TP53 cells after amiloride exposure. On the other hand, we did not find a significant systemic toxicity in mice treated with amiloride. [Conclusions]: Overall, our results demonstrate the antimyeloma activity of amiloride and provide a mechanistic rationale for its use as an alternative treatment option for relapsed multiple myeloma patients, especially those with 17p deletion or TP53 mutations that are resistant to current therapies.
Identifiersdoi: 10.1158/1078-0432.CCR-17-0678
e-issn: 1557-3265
issn: 1078-0432
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

PubMed Central

checked on Jan 21, 2022


checked on Jan 17, 2022


checked on Jan 20, 2022

Page view(s)

checked on Jan 24, 2022


checked on Jan 24, 2022

Google ScholarTM




Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.